Design Therapeutics Inc (DSGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2017 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 21,200 | 26,500 | 298,569 | 2,379 | N/A |
| Marketable Securities | 260,598 | 303,887 | 85,495 | 33,712 | N/A |
| TOTAL | $284,584 | $335,119 | $385,435 | $36,233 | $N/A |
| Non-Current Assets | |||||
| PPE Net | 1,691 | 1,947 | 1,508 | 71 | N/A |
| Other Non-Current Assets | 3,368 | 4,071 | 3,614 | 212 | 0 |
| TOTAL | $5,059 | $6,018 | $5,122 | $283 | $N/A |
| Total Assets | $289,643 | $341,137 | $390,557 | $36,516 | $N/A |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,940 | 3,025 | 1,620 | 1,399 | 0 |
| Accrued Expenses | 7,682 | 7,751 | 3,663 | 931 | N/A |
| TOTAL | $9,622 | $10,776 | $5,283 | $2,330 | $N/A |
| Non-Current Liabilities | |||||
| aiOther Non-Current Liabilities | 2,334 | 3,051 | 3,144 | 45,501 | 0 |
| TOTAL | $2,334 | $3,051 | $3,144 | $45,501 | $N/A |
| Total Liabilities | $11,956 | $13,827 | $8,427 | $47,831 | $N/A |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 56,494 | 55,943 | 55,700 | N/A | N/A |
| Common Shares | 6 | 6 | 6 | 1 | N/A |
| Retained earnings | -177,626 | -110,764 | -47,456 | -11,923 | N/A |
| Other shareholders' equity | 62 | -3,356 | -244 | 156 | 0 |
| TOTAL | $277,687 | $327,310 | $382,130 | $-11,315 | $N/A |
| Total Liabilities And Equity | $289,643 | $341,137 | $390,557 | $36,516 | $0 |